US Judge Pauses Louisiana's Challenge to FDA Abortion Drug Rule

The state's lawsuit seeking to limit access to the abortion pill mifepristone is on hold while the FDA reviews the drug's safety.

Apr. 8, 2026 at 12:45am

Got story updates? Submit your updates here. ›

A dimly lit, cinematic interior space with warm sunlight streaming through windows, creating deep shadows and a sense of solemnity, conveying the gravity of the political and legal issues surrounding access to abortion medication.The legal battle over access to abortion medication continues, as a federal judge pauses a state's challenge to the FDA's rules amid an ongoing federal review.Lafayette Today

A federal judge in Louisiana has paused the state's lawsuit challenging the FDA's 2023 rule that allows the abortion pill mifepristone to be dispensed through the mail. The judge said the case should not proceed until the FDA completes its review of the drug's safety, which has reportedly been delayed until after the November midterm elections.

Why it matters

The ruling is a setback for Louisiana's efforts to restrict access to medication abortion, which has become more common since the Supreme Court overturned Roe v. Wade. The case is part of a broader legal battle over abortion rights and regulations in the post-Roe landscape.

The details

U.S. District Judge David Joseph in Lafayette, Louisiana, denied the state's motion to block the 2023 FDA rule pending the outcome of the case, but said Louisiana could renew the motion when the case resumes. The judge said the public interest is best served by waiting for the FDA's review of mifepristone's safety, rather than 'government by lawsuit'.

  • The FDA launched a review of mifepristone, which it first approved in 2000, last year.
  • The FDA's review of mifepristone has reportedly been delayed until after the November 2026 midterm elections.

The players

U.S. District Judge David Joseph

The federal judge presiding over Louisiana's lawsuit challenging the FDA's 2023 rule on mifepristone.

Liz Murrill

The Republican Attorney General of Louisiana who filed the lawsuit against the FDA.

GenBioPro

A drug company that has intervened in Louisiana's lawsuit to defend the FDA regulation allowing mifepristone to be dispensed through the mail.

Danco Laboratories

A drug company that has intervened in Louisiana's lawsuit to defend the FDA regulation allowing mifepristone to be dispensed through the mail.

Got photos? Submit your photos here. ›

What they’re saying

“'At this juncture, it is the completion of FDA's promised good faith, evidence-based, and expeditious review [and] not 'government by lawsuit' that this Court finds to be in the public interest.'”

— U.S. District Judge David Joseph

What’s next

The FDA is expected to complete its review of mifepristone's safety after the November 2026 midterm elections, at which point the Louisiana case could resume.

The takeaway

This ruling is a temporary setback for Louisiana's efforts to limit access to medication abortion, as the judge has paused the state's lawsuit pending the FDA's review of mifepristone. The case is part of a broader legal battle over abortion rights in the post-Roe landscape.